IMMX
Immix Biopharma, Inc.·Healthcare
8.73
1.244%(−0.11)
Close PriceLast Updated: — ET
52W L: $1.8752W H: $11.61
IMMX NEWS
zacks.com
10h ago
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
globenewswire.com
5d ago
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
- Financing includes leading U. S. biotechnology institutional investors and mutual funds - LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.
globenewswire.com
5d ago
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.
globenewswire.com
6d ago
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.
globenewswire.com
6d ago
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patients who have reached CR – – All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month – – Next NEXICART-2 Update Expected Late September, 2026 – LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The NEXICART-2 CR rate is now 95% (19 out of 20 patients).
globenewswire.com
Apr 9
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
